Pangenomic Health Inc.
NARA
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 105.92% | 29.44% | -15.94% | -68.49% | -55.29% |
| Gross Profit | -105.92% | -29.44% | 15.94% | 68.49% | 55.29% |
| SG&A Expenses | -20.89% | -55.05% | -70.44% | -60.61% | -65.74% |
| Depreciation & Amortization | -80.43% | -56.52% | -31.87% | -6.67% | 3.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.65% | -34.36% | -60.01% | -65.48% | -66.67% |
| Operating Income | -12.65% | 34.36% | 60.01% | 65.48% | 66.67% |
| Income Before Tax | 51.75% | -82.30% | -25.68% | 70.43% | 70.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.75% | -82.30% | -25.68% | 70.43% | 70.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.75% | -82.30% | -25.68% | 70.43% | 70.27% |
| EBIT | -12.65% | 34.36% | 60.01% | 65.48% | 66.67% |
| EBITDA | -13.57% | 34.22% | 60.14% | 65.71% | 66.89% |
| EPS Basic | 74.39% | 35.70% | 50.77% | 88.21% | 86.94% |
| Normalized Basic EPS | 65.41% | 78.08% | 80.91% | 75.89% | 75.16% |
| EPS Diluted | 74.39% | 35.70% | 50.77% | 88.21% | 86.94% |
| Normalized Diluted EPS | 65.41% | 78.08% | 80.91% | 75.89% | 75.16% |
| Average Basic Shares Outstanding | 180.82% | 202.96% | 143.55% | 115.27% | 73.12% |
| Average Diluted Shares Outstanding | 180.82% | 202.96% | 143.55% | 115.27% | 73.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |